Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site

por Petrunak, Elyse M., Bart, Aaron G., Peng, Hwei-Ming, Auchus, Richard J., Scott, Emily E.
Publicado 2023

Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

por Bonomo, Silvia, Hansen, Cecilie H., Petrunak, Elyse M., Scott, Emily E., Styrishave, Bjarne, Jørgensen, Flemming Steen, Olsen, Lars
Publicado 2016